WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, delivers life science companies industry-specific data ...

In conversation with Fierce Pharma, Anthony Billinger, senior director of Compass Strategy at Veeva Systems, sheds light on the rapidly evolving world of commercial data in life sciences—and why the ...

Generative AI-driven analytics platform brings together owned and public data with Oracle Health Real-World Data's millions of de-identified longitudinal EHR records Delivers powerful, deep insights ...

Management indicated they "plan to deliver multiple near-term updates that assess blood-based biomarkers of metabolic health, body composition and weight loss across multiple cohorts." Data from the ...

Wave Life Sciences presented promising preclinical data at the American Diabetes Association's 85th Annual Scientific Sessions, highlighting WVE-007, a GalNAc-siRNA therapy targeting INHBE as a ...

The future of healthcare is here—and it’s digital. From accelerating research to improving patient care, the integration of AI, data analytics and cutting-edge technologies is driving the industry ...

NashBio, a pioneer in genomics and real-world data, is transforming life sciences research by making complex healthcare data more accessible. Co-founded by Leeland Ekstrom, NashBio leverages ...

The Case Western Reserve University School of Medicine and Case School of Engineering, in collaboration with Tohoku University (Japan), invite members of the community to the sixth annual Data Science ...

The data landscape is expanding far more quickly than anyone could have expected. With 30% of data creation coming from the healthcare and life sciences sector, how are IT organizations addressing the ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531, showing >5% dystrophin production. The safety profile of WVE-N531 is ...